96 related articles for article (PubMed ID: 24953475)
1. Adverse drug reaction: pomalidomide-induced liver injury.
Veluswamy RR; Ward SC; Yum K; Abramovitz RB; Isola LM; Jagannath S; Parekh S
Lancet; 2014 Jun; 383(9935):2125-6. PubMed ID: 24953475
[No Abstract] [Full Text] [Related]
2. Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Reed-Guy L; Hoteit MA; Garfall AL
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e337-e338. PubMed ID: 29907543
[No Abstract] [Full Text] [Related]
3. Thalidomide-induced severe hepatotoxicity.
Dabak V; Kuriakose P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):583-5. PubMed ID: 19083237
[No Abstract] [Full Text] [Related]
4. Pomalidomide. A last-line treatment option for multiple myeloma.
Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Vilas-Boas F; Gonçalves R; Sobrinho Simões M; Lopes J; Macedo G
Gastroenterol Hepatol; 2012 Oct; 35(8):560-6. PubMed ID: 22789729
[TBL] [Abstract][Full Text] [Related]
6. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Sinha S; Lacy M; Mikhael J; Hayman S; Buadi F; Detweiler-Short K; Dispenzieri A; Gertz M; Dingli D; Rajkumar SV; Kumar SK
Leukemia; 2012 Apr; 26(4):839-41. PubMed ID: 21986842
[No Abstract] [Full Text] [Related]
7. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
9. An overview of the progress in the treatment of multiple myeloma.
Kyle RA; Rajkumar SV
Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
[TBL] [Abstract][Full Text] [Related]
10. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide-induced severe hepatotoxicity.
Hanje AJ; Shamp JL; Thomas FB; Meis GM
Pharmacotherapy; 2006 Jul; 26(7):1018-22. PubMed ID: 16803426
[TBL] [Abstract][Full Text] [Related]
12. New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Jagannath S
Clin Adv Hematol Oncol; 2009 Mar; 7(3):178-9. PubMed ID: 19398940
[No Abstract] [Full Text] [Related]
13. Targeted therapy of multiple myeloma.
Kyle RA
Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Roy V; Stewart AK; Bergsagel PL; Dispenzieri A; Laumann K; Allred J; Lacy MQ; Fonseca R; Reeder CB; Kumar S; Rivera CE; Gertz MA; Buadi FK; Hayman SR; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e294. PubMed ID: 25794130
[No Abstract] [Full Text] [Related]
15. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Geng C; Hou J; Zhao Y; Ke X; Wang Z; Qiu L; Xi H; Wang F; Wei N; Liu Y; Yang S; Wei P; Zheng X; Huang Z; Zhu B; Chen WM
Am J Hematol; 2014 Nov; 89(11):1037-42. PubMed ID: 25092564
[TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
[No Abstract] [Full Text] [Related]
19. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
20. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
